Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis

Barry G. Arnason, Regina Berkovich, Anna Catania, Robert P. Lisak, Mone Zaidi

Research output: Contribution to journalArticlepeer-review

Abstract

The therapeutic benefits of adrenocorticotropic hormone in multiple sclerosis are usually ascribed to its corticotropic actions. Evidence is presented that adrenocorticotropic hormone, approved for multiple sclerosis relapses, acts via corticosteroid-independent melanocortin pathways to engender down-modulating actions on immune-system cells and the cytokines they synthesize. Immune response-dampening effects are also brought about by agent-induced neurotransmitters that inhibit immunocytes. The likelihood that adrenocorticotropic hormone promotes microglial quiescence and counteracts glucocorticoid-mediated bone resorption is discussed.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalMultiple Sclerosis Journal
Volume19
Issue number2
DOIs
Publication statusPublished - 2013

Keywords

  • ACTH
  • corticosteroids
  • melanocortin signaling
  • melanocortins
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint

Dive into the research topics of 'Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis'. Together they form a unique fingerprint.

Cite this